"Horizon 2020 - the Framework Programme for Research and Innovation". Infoday 12. července 2012, Praha Judita Kinkorová Obsah prezentace 7. rámcový program 2007 2013 (7RP) Kontext Horizontu 2020 Hlavní rysy Horizontu 2020 Priority Horizontu 2020 Novinky Horizontu 2020 Informační zdroje 2 7. Rámcový program pro VaV 7. RP pro výzkum, technologický rozvoj a demonstrace (2007 2013) rozpočet: 50,5 mld. největší unijní (komunitární) program hlavní nástroj financování evropského výzkumu podpora evropského výzkumu s cílem posílit konkurenceschopnost Evropy 4 specifické programy Spolupráce, Myšlenky, Lidé, Kapacity 3 1
FP versus HORIZON 2020 FP7 HORIZON 2020 4 specific FP7 programmes Billion Cooperation Ideas Ideas People 10 thematic programmes basic research (ERC) Mobility (Marie Curie actions) 32.4 7.5 4.7 3 priorities Excellent Science Competitive Industries Better Society Capacities 7 horizontal axes 4.1 4 Cooperation Priorities 1. Health 2. Food, agriculture and biotechnology 3. Information and communication technologies 4. Nanosciences, nanotechnologies, materials and new production technologies 5. Energy 6. Environment (including climate change) 7. Transport (including aeronautics) 8. Socio-economic sciences and the humanities 9. Security and space FP7 versus Horizon 2020 Better Society challenges Health, demographic change and wellbeing; Food security, sustainable agriculture, marine and maritime research, and the bio-economy; Secure, clean and efficient energy; Smart, green and integrated transport; Inclusive, innovative and secure societies; Climate action, resource efficiency and raw materials. 5 Novinky H 2020 80.2 Billion marked in the Commission proposals for 2014-2020 EU budget (June 2011) Covering current funding for: The 7th Framework Programme The Competitiveness and Innovation Framework Programme (CIP) The European Institute for Innovation and Technology (EIT) And strengthening complementarities with the Structural Funds 6 2
Societal challenges Proposed funding (million euro, 2014-20) Health, demographic change and wellbeing 8 033 Food security, sustainable agriculture, marine and maritime research & the bioeconomy 4 152 Secure, clean and efficient energy* 5 782 Smart, green and integrated transport 6 802 Climate action, resource efficiency and raw materials 3 160 Inclusive, innovative and secure societies 3 819 7 Main Specific Challenges Considered 1. Prevention Better understanding and management of the relationship between environment, behaviour, nutrition, genetics and their contribution to health and disease. Facilitating active and healthy ageing, and the prevention, delay and attenuation of disease and disability with tools and services including those supporting self care. 8 Main Specific Challenges Considered 2. Combating and curing disease Better understanding the mechanisms of disease and redefining their taxonomies Better understanding of the normal processes of human growth and development Promoting conditions favouring drug discovery and development (through public private partnerships) The development and validation of innovative therapies, medical technologies, and vaccines and diagnostics 9 3
Main Specific Challenges Considered 3. Increasing the sustainability and efficiency of the health and social care sector Research in health systems, investment in capacity building, exchange of information between national systems, technology and quality assessments, investigation of health interventions, the socioeconomic impacts of health and disease. Assistive and independent living solutions, ethics, service innovation, and societal uptake of innovation. Enhancing preparedness for emerging epidemics and other emerging health threats. 10 /1/ Overarching features considered: Provision for the long-term study of well characterised, large populations; data collection and processing. Development of and support for both biological and data infastructures (bio-banks, cohorts, animal models, etc.) and for other medical research facilities and infrastructures. Support for the development of tools and technologies including omics, high throughput research, systems biology and imaging, and for research using these. 11 /2/ Overarching features considered: Support for regulatory sciences (drug safety, clinical trials, cell & gene therapies, specialist manufacturing, etc.) Support for converting knowledge into innovation, for the improvement of clinical practice and the development of marketable products and services. 12 4
International co-operation: Major strategic international initiatives to be pursued, including: Be a leader in large worldwide research consortia EDCTP-2, Rare Diseases (International Rare Diseases Research Consortium - IRDiRC), International Human Microbiome Consortium IHMC, International Initiative for Traumatic Brain Injury Research InTBIR, Trans-Atlantic Task Force on antimicrobial resistance TATFAR, etc., to improve availability of interventions 13 Další kroky Právě se děje: Vyjednávání Parlamentu a Rady o návrzích Komise Následně: Vyjednávání Parlamentu a Rady o rozpočtu EU 2014-2020 (včetně rozpočtu pro Horizont 2020) Polovina roku 2012: Poslední výzvy na základě Sedmého rámcového programu pro výzkum s cílem umožnit návaznost Horizontu 2020 Koncem roku 2013: Přijetí legislativy k programu Horizont 2020 Parlamentem a Radou 1/1/2014: Začíná Horizont 2020; zveřejnění prvních výzev 14 Informační zdroje Horizont 2020 http://cordis.europa.eu/fp7/ Cordis http://cordis.europa.eu/fp7/ http://cordis.europa.eu/partners-service/ Evropská komise http://ec.europa.eu/research Research Participant Portal http://ec.europa.eu/research/participants/portal/page/home Kontakty v ČR http://www.fp7.cz http://www.czelo.cz 15 5
Technologické centrum AV ČR Ve Struhách 27 160 00 Praha 6 Judita KINKOROVÁ kinkorova@tc.cz, 234 006 108 16 6